

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 05-May-2022
 Document Type: USP Monographs
 DocId: GUID-9DD0CE42-2794-464E-ABD9-6CF1475FA5E1_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M52980_04_01
 DOI Ref: 8xg9u

© 2025 USPC
 Do not distribute

Methylprednisolone Sodium Succinate for Injection

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click www.uspnf.com/rb-methylprednisolone-na-succinate-for-inj-20220527.

Change to read:

DEFINITION

Methylprednisolone Sodium Succinate for Injection is a sterile mixture of Methylprednisolone Sodium Succinate with suitable buffers. It may be prepared from Methylprednisolone Sodium Succinate or from Methylprednisolone Hemisuccinate with the aid of Sodium Hydroxide,

▲Sodium Bicarbonate,▲ (RB 5-May-2022) or Sodium Carbonate. It contains the equivalent of NLT 90.0% and NMT 110.0% of the labeled amount of methylprednisolone ($C_{22}H_{30}O_5$) in the volume of constituted solution designated on the label.

IDENTIFICATION

• A. INFRARED ABSORPTION

Sample: Nominally 100 mg of methylprednisolone sodium succinate from Methylprednisolone Sodium Succinate for Injection

Analysis: Transfer the *Sample* to a separator, dissolve in 10 mL of [water](#), add 1 mL of 3 N [hydrochloric acid](#), and extract immediately with 50 mL of [chloroform](#). Filter the [chloroform](#) extract through cotton, evaporate on a steam bath to dryness, and dry under vacuum at 60° for 3 h.

Acceptance criteria: The IR absorption spectrum of a mineral oil dispersion of the residue so obtained exhibits maxima only at the same wavelengths as those of a similar preparation of [USP Methylprednisolone Hemisuccinate RS](#).

ASSAY

• PROCEDURE

Diluent: [Chloroform](#) and [glacial acetic acid](#) (97:3)

Mobile phase: [Butyl chloride](#), water-saturated [butyl chloride](#), [tetrahydrofuran](#), [methanol](#), and [glacial acetic acid](#) (95:95:14:7:6)

Standard stock solution: 0.30 mg/mL of [USP Methylprednisolone RS](#) in *Diluent*

Internal standard solution: 3 mg/mL of [USP Fluorometholone RS](#) in [tetrahydrofuran](#)

Standard solution: 0.65 mg/mL of [USP Methylprednisolone Hemisuccinate RS](#) prepared as follows. Transfer an appropriate amount of [USP Methylprednisolone Hemisuccinate RS](#) to a suitable volumetric flask. Pipet 10% of the flask volume of the *Internal standard solution* and 10% of the flask volume of the *Standard stock solution*. Dilute with *Diluent* to volume.

Sample solution: Transfer a suitable quantity of constituted solutions (mix the constituted solutions prepared from the contents of 10 vials of Methylprednisolone Sodium Succinate for Injection) equivalent to 50 mg of methylprednisolone to a suitable flask containing 10.0 mL of the *Internal standard solution*, and dilute with *Diluent* to 100.0 mL. Shake thoroughly for 5 min, then allow the phases to separate, discarding the upper phase.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm × 30-cm; packing [L3](#)

Flow rate: 1 mL/min

Injection volume: 6 µL

[NOTE—The order of elution of peaks in the *Standard solution* is as follows. Internal standard peak, methylprednisolone hemisuccinate peak, and successive smaller peaks of free methylprednisolone and methylprednisolone 17-hemisuccinate.]

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of methylprednisolone ($C_{22}H_{30}O_5$) in the portion of constituted Methylprednisolone Sodium Succinate for Injection taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

R_U = ratio of the sum of the peak areas for methylprednisolone hemisuccinate and methylprednisolone 17-hemisuccinate to the peak area of the internal standard from the *Sample solution*

R_S = ratio of the sum of the peak areas for methylprednisolone hemisuccinate and methylprednisolone 17-hemisuccinate to the peak area of the internal standard from the *Standard solution*

C_s = concentration of [USP Methylprednisolone Hemisuccinate RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of methylprednisolone in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of methylprednisolone, 374.47

M_{r2} = molecular weight of methylprednisolone hemisuccinate, 474.54

To this calculated amount, add the percentage of free methylprednisolone found in the test for *Free Methylprednisolone*.

Acceptance criteria: 90.0%–110.0%

OTHER COMPONENTS

• FREE METHYLPREDNISOLONE

Analysis

Samples: *Standard solution* and *Sample solution*

Using the chromatograms obtained in the Assay, measure the areas of the peaks from the internal standard and free methylprednisolone. Calculate the percentage of free methylprednisolone in the portion of *Sample solution* taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

R_U = peak area ratio of the free methylprednisolone to the internal standard from the *Sample solution*

R_S = peak area ratio of the free methylprednisolone to the internal standard from the *Standard solution*

C_s = concentration of [USP Methylprednisolone RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of methylprednisolone in the *Sample solution* (mg/mL)

Acceptance criteria: The amount of free methylprednisolone is NMT 6.6% of the labeled amount of methylprednisolone ($C_{22}H_{30}O_5$).

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

SPECIFIC TESTS

- [pH \(791\)](#)

Sample solution: 50 mg/mL of methylprednisolone sodium succinate

Acceptance criteria: 7.0–8.0

- [STERILITY TESTS \(71\)](#): Meets the requirements
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): NMT 0.17 USP Endotoxin Units/mg of methylprednisolone
- [LOSS ON DRYING \(731\)](#)

Analysis: Dry at 105° for 3 h.

Acceptance criteria: NMT 2.0%

- **CONSTITUTED SOLUTION:** At the time of use, it meets the requirements for [Injections and Implanted Drug Products \(1\)](#), [Specific Tests, Completeness and Clarity of Solutions](#).
- [PARTICULATE MATTER IN INJECTIONS \(788\)](#): Meets the requirements for small-volume injections
- **OTHER REQUIREMENTS:** Meets the requirements in [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#)

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging, Packaging for Constitution](#).
- [USP REFERENCE STANDARDS \(11\)](#)
[USP Fluorometholone RS](#)
[USP Methylprednisolone RS](#)
[USP Methylprednisolone Hemisuccinate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|---|---|---------------------------|
| METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION | Documentary Standards Support | SM52020 Small Molecules 5 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(4)

Current DocID: GUID-9DD0CE42-2794-464E-ABD9-6CF1475FA5E1_4_en-US

DOI: https://doi.org/10.31003/USPNF_M52980_04_01

DOI ref: [8xg9u](#)

OFFICIAL